Drug Trial Radar · NCT07760831
A Trial of HRS-7085 Tablets in Patients With Moderate to Severe Active Ulcerative Colitis
Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
8
Planned (sponsor's estimate)
Start
Aug 2026
Primary completion
Apr 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the safety, tolerability and pharmakokinetics of HRS-7085 in adults.
Conditions
- Moderate to Severe Ulcerative Colitis
Interventions
HRS-7085 tabletsDrug
HRS-7085 tablets
PlaceboDrug
HRS-7085 tablet blank preparation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs)Time frame: at Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
IMSP Republican Clinical Hospital "Timofei Mosneaga", Clinical Trial Unit ARENSIA EXPLORATORY MEDICINE
Chisinau, Chișinău Municipality, Moldova
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.